Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

FOR DRUG CONSULTING : revenue, balance sheet and financial ratios

FOR DRUG CONSULTING is a French company founded 21 years ago, specialized in the sector Conseil pour les affaires et autres conseils de gestion. Based in MALAKOFF (92240), this company of category PME shows in 2019 a net income positive of 44 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-18

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - FOR DRUG CONSULTING (SIREN 478862956)
Indicator 2019 2018
Revenue N/C N/C
Net income 44 382 € 65 106 €
EBITDA N/C N/C
Net margin N/C N/C

Revenue and income statement

In 2019, FOR DRUG CONSULTING generates positive net income of 44 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2018-2019: 65 k€ -> 44 k€.

Net income (2019) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

44 382 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 101%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 31%. The balance between equity and debt is satisfactory.

Debt ratio (2019) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

100.739%

Financial autonomy (2019) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

30.913%

Asset age ratio (2019) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

42.7%

Solvency indicators evolution
FOR DRUG CONSULTING

Sector positioning

Debt ratio
100.74 2019
2018
2019
Q1: 0.0
Med: 4.29
Q3: 44.13
Average

In 2019, the debt ratio of FOR DRUG CONSULTING (100.74) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
30.91% 2019
2018
2019
Q1: 5.58%
Med: 39.62%
Q3: 73.61%
Average

In 2019, the financial autonomy of FOR DRUG CONSULTING (30.9%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 238.06. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2019) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

238.056

Liquidity indicators evolution
FOR DRUG CONSULTING

Sector positioning

Liquidity ratio
238.06 2019
2018
2019
Q1: 136.05
Med: 274.14
Q3: 675.52
Average +7 pts over 2 years

In 2019, the liquidity ratio of FOR DRUG CONSULTING (238.06) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Positioning of FOR DRUG CONSULTING in its sector

Comparison with sector Conseil pour les affaires et autres conseils de gestion

Valuation estimate

Based on 73 transactions of similar company sales in 2019, the value of FOR DRUG CONSULTING is estimated at 173 691 € (range 86 318€ - 387 587€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2019
73 tx
86k€ 173k€ 387k€
173 691 € Range: 86 318€ - 387 587€
NAF 5 année 2019

Valuation method used

Net Income Multiple
44 382 € × 3.9x = 173 692 €
Range: 86 318€ - 387 588€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 73 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Conseil pour les affaires et autres conseils de gestion)

Compare FOR DRUG CONSULTING with other companies in the same sector:

Voir toutes les statistiques du secteur Conseil pour les affaires et autres conseils de gestion

Frequently asked questions about FOR DRUG CONSULTING

What is the revenue of FOR DRUG CONSULTING ?

The revenue of FOR DRUG CONSULTING is not publicly disclosed (confidential accounts filed with INPI).

Is FOR DRUG CONSULTING profitable?

Yes, FOR DRUG CONSULTING generated a net profit of 44 k€ in 2019.

Where is the headquarters of FOR DRUG CONSULTING ?

The headquarters of FOR DRUG CONSULTING is located in MALAKOFF (92240), in the department Hauts-de-Seine.

Where to find the tax return of FOR DRUG CONSULTING ?

The tax return of FOR DRUG CONSULTING is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does FOR DRUG CONSULTING operate?

FOR DRUG CONSULTING operates in the sector Conseil pour les affaires et autres conseils de gestion (NAF code 70.22Z). See the 'Sector positioning' section above to compare the company with its competitors.